Humacyte, Inc. Operating Cash Flow
Humacyte, Inc. (HUMA) reported Operating Cash Flow of -$47.16 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-12
- Humacyte, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$22.06M.
- Humacyte, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$25.10M.
- Humacyte, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$26.12M.
- Humacyte, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$23.90M.
- Humacyte, Inc. net cash provided by (used in) operating activities for fiscal 2025 was -$105.04M.
- Humacyte, Inc. net cash provided by (used in) operating activities for fiscal 2024 was -$98.12M.
- Humacyte, Inc. net cash provided by (used in) operating activities for fiscal 2023 was -$73.31M.
- Humacyte, Inc. net cash provided by (used in) operating activities for fiscal 2022 was -$71.13M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 3 month as first filed | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 6 month as first filed | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|---|---|
| 2026-06-30 | -$22.06M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | -$47.16M 10-Q · filed 2026-08-12 | -$73.29M derived: sum of 3 quarters · filed 2026-08-12 | -$97.19M derived: sum of 4 quarters · filed 2026-08-12 | ||
| 2026-03-31 | -$25.10M 10-Q · filed 2026-05-13 | -$51.23M derived: sum of 2 quarters · filed 2026-05-13 | -$75.13M derived: sum of 3 quarters · filed 2026-05-13 | -$101.55M derived: sum of 4 quarters · filed 2026-08-12 | ||
| 2025-12-31 | -$26.12M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | -$50.03M derived: sum of 2 quarters · filed 2026-03-27 | -$76.44M derived: sum of 3 quarters · filed 2026-08-12 | -$105.04M 10-K · filed 2026-03-27 | ||
| 2025-09-30 | -$23.90M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$50.32M derived: sum of 2 quarters · filed 2026-08-12 | -$78.92M 10-Q · filed 2025-11-12 | -$105.50M derived: sum of 4 quarters · filed 2026-08-12 | ||
| 2025-06-30 | -$26.41M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | -$55.01M 10-Q · filed 2026-08-12 | -$81.59M derived: sum of 3 quarters · filed 2026-08-12 | -$104.50M derived: sum of 4 quarters · filed 2026-08-12 | ||
| 2025-03-31 | -$28.60M 10-Q · filed 2026-05-13 | -$55.18M derived: sum of 2 quarters · filed 2026-05-13 | -$78.08M derived: sum of 3 quarters · filed 2026-05-13 | -$99.38M derived: sum of 4 quarters · filed 2026-05-13 | ||
| 2024-12-31 | -$26.58M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | -$49.48M derived: sum of 2 quarters · filed 2026-03-27 | -$70.78M derived: sum of 3 quarters · filed 2026-03-27 | -$98.12M 10-K · filed 2026-03-27 | ||
| 2024-09-30 | -$22.91M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$44.20M derived: sum of 2 quarters · filed 2025-11-12 | -$71.55M 10-Q · filed 2025-11-12 | -$90.60M derived: sum of 4 quarters · filed 2025-11-12 | ||
| 2024-06-30 | -$21.29M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | -$48.64M 10-Q · filed 2025-08-11 | -$67.69M derived: sum of 3 quarters · filed 2025-08-11 | -$80.70M derived: sum of 4 quarters · filed 2025-08-11 | ||
| 2024-03-31 | -$27.35M 10-Q · filed 2025-05-13 | -$46.40M derived: sum of 2 quarters · filed 2025-05-13 | -$59.41M derived: sum of 3 quarters · filed 2025-05-13 | -$82.01M derived: sum of 4 quarters · filed 2025-05-13 | ||
| 2023-12-31 | -$19.05M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | -$32.06M derived: sum of 2 quarters · filed 2025-03-31 | -$54.66M derived: sum of 3 quarters · filed 2025-03-31 | -$73.31M 10-K · filed 2025-03-31 | ||
| 2023-09-30 | -$13.01M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-08 | -$35.61M derived: sum of 2 quarters · filed 2024-11-08 | -$54.25M 10-Q · filed 2024-11-08 | -$73.21M derived: sum of 4 quarters · filed 2024-11-08 | ||
| 2023-06-30 | -$22.60M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | -$41.24M 10-Q · filed 2024-08-13 | -$60.20M derived: sum of 3 quarters · filed 2024-08-13 | -$77.01M derived: sum of 4 quarters · filed 2024-08-13 | ||
| 2023-03-31 | -$18.64M 10-Q · filed 2024-05-13 | -$37.60M derived: sum of 2 quarters · filed 2024-05-13 | -$54.40M derived: sum of 3 quarters · filed 2024-05-13 | -$70.97M derived: sum of 4 quarters · filed 2024-05-13 | ||
| 2022-12-31 | -$18.96M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | -$35.76M derived: sum of 2 quarters · filed 2024-03-28 | -$52.33M derived: sum of 3 quarters · filed 2024-03-28 | -$71.13M 10-K · filed 2024-03-28 | ||
| 2022-09-30 | -$16.80M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | -$33.37M derived: sum of 2 quarters · filed 2023-11-09 | -$52.17M 10-Q · filed 2023-11-09 | -$73.62M derived: sum of 4 quarters · filed 2023-11-09 | ||
| 2022-06-30 | -$16.57M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | -$35.37M 10-Q · filed 2023-08-14 | -$56.81M derived: sum of 3 quarters · filed 2023-08-14 | -$87.33M derived: sum of 4 quarters · filed 2023-08-14 | ||
| 2022-03-31 | -$18.80M 10-Q · filed 2023-05-12 | -$40.24M derived: sum of 2 quarters · filed 2023-05-12 | -$70.76M derived: sum of 3 quarters · filed 2023-05-12 | -$85.44M derived: sum of 4 quarters · filed 2023-05-12 | ||
| 2021-12-31 | -$21.45M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-24 | -$51.97M derived: sum of 2 quarters · filed 2023-03-24 | -$66.65M derived: sum of 3 quarters · filed 2023-03-24 | -$81.19M 10-K · filed 2023-03-24 | ||
| 2021-09-30 | -$30.52M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | -$45.20M derived: sum of 2 quarters · filed 2022-11-10 | -$59.74M 10-Q · filed 2022-11-10 | -$59.97M derived: sum of 4 quarters · filed 2022-11-10 | ||
| 2021-06-30 | -$14.68M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-12 | -$29.22M 10-Q · filed 2022-08-12 | -$616.23K 10-Q · filed 2021-08-16 | -$29.45M derived: sum of 3 quarters · filed 2022-08-12 | -$29.47M derived: sum of 4 quarters · filed 2022-08-12 | |
| 2021-03-31 | -$14.54M 10-Q · filed 2022-05-13 | -$493.74K 10-Q · filed 2021-05-17 | -$14.77M derived: sum of 2 quarters · filed 2022-05-13 | -$14.79M derived: sum of 3 quarters · filed 2022-05-13 | ||
| 2020-12-31 | -$227.61K derived: 10-K/A 6 month − 10-Q 3 month · filed 2021-05-14 | -$245.66K 10-K/A · filed 2021-05-14 | -$55.57M 10-K · filed 2022-03-29 | |||
| 2020-09-30 | -$18.05K 10-Q · filed 2020-11-13 | -$40.37M 10-Q · filed 2021-11-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |